0940 GMT - Novartis's positive late-stage results for its blood-disorder treatment Fabhalta speak for the efficacy of the drug in treating other diseases, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's drug, already approved for chronic kidney disorder, is currently being tested in two rare kidney diseases. "Novartis sees peak sales for the drug of $3+ billion--which we roughly match in our modeling--but still risk adjust our revenue estimates by 40% in indications, where we have not yet seen clinical data," the analyst says. Shares fall 0.2% to 90.23 Swiss francs. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
December 06, 2024 04:43 ET (09:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。